Who
Rachel K. King
Director
Company insider
Files Form 4 as: Director, Fulcrum Therapeutics; Director, Novavax; President, CEO, Crescent Biopharma.
In numbers
- Trades disclosed
- 72
- Buys
- 2
- Sells
- 2
- Bought
- $143K
- Sold
- $367K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 9 Jan 2014
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —18,880 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,880 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,880 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —18,880 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,270 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,180 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,270 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,180 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | $182K28,326 at $6.42 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,884 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,420 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —10,420 at $0.00 | filing |
| 13 Dec 2024filed 2 Jan 2025 | NVAX NovavaxBiotechnology | SEC FORM 4 Sold | $37K4,150 at $9.02 | filing |
| 12 Nov 2024filed 14 Nov 2024 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,670 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | $248K15,630 at $15.86 | filing |
| 12 Jun 2024filed 14 Jun 2024 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,420 at $0.00 | filing |
News
Himanshu Shah Shifts to Family Office, Ends Novavax ActivismNVAX · indiawest.com · 23 Oct 2026Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)NVAX · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Rachel K. King; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.